Review articleThalidomide: A review of approved and investigational uses
References (221)
Thalidomide and congenital abnormalities
Lancet
(1961)Thalidomide and congenital abnormalities
Lancet
(1962)- et al.
Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin
J Pharm Sci.
(1992) - et al.
Determination of thalidomide by high performance liquid chromatography: Methodological strategy for clinical trials
Clin Biochem.
(1995) - et al.
Management of erythema nodosum leprosum by thalidomide: Thalidomide analogues inhibit M. leprae-induced TNF α production in vitro
Biomed Pharmacother.
(2002) - et al.
Thalidomide in toxic epidermal necrolysis
Lancet
(1999) - et al.
Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes
J Am Acad Dermatol.
(1984) - et al.
Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
Biochem Pharmacol.
(1998) - et al.
Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity
J Biol Chem.
(2001) - et al.
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Blood
(2001)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Blood
(2000)
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
Immunopharmacology
(1996)
Erythema nodosum in leprosy
J Chronic Dis.
(1963)
Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells
Life Sci.
(1994)
Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
Biol Blood Marrow Transplant
(2001)
Thalidomide as salvage therapy for chronic graft-versus-host disease
Blood
(1995)
Thalidomide for treatment of patients with chronic graft-versus-host disease
Blood
(2000)
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
J Am Acad Dermatol.
(1995)
Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement
Clin Immunol.
(2002)
Immune stimulation in scleroderma patients treated with thalidomide
Clin Immunol.
(2000)
Lichen planopilaris treated with thalidomide
J Am Acad Dermatol.
(2001)
Recalcitrant pyoderma gangrenosum treated with thalidomide
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Lancet
(1998)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a Phase 2 study of 169 patients
Blood
(2001)
Thalidomide in refractory and relapsing multiple myeloma
Semin Oncol.
(2001)
Dark Remedy. The Impact of Thalidomide and Its Revival as a Vital Medicine
N Engl J Med.
(2001)
Thalidomide in the treatment of lepra reactions
Clin Pharmacol Ther.
(1965)
Results of a double blind study of the influence of thalidomide on the lepra reaction
Int J Lepr Other Mycobact Dis.
(1969)
Thalomid capsules
(2001)
Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man
J Pharm Pharmacol.
(2000)
Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis
Chirality
(1998)
Handling of blood samples for determination of thalidomide
Clin Chem.
(1997)
Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
Chirality
(1995)
Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers
J Clin Pharmacol.
(1999)
Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone
Clin Pharmacol Ther.
(1998)
Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics
Clin Pharmacol Ther.
(1999)
Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects
AIDS Res Hum Retroviruses
(1999)
Thalidomide dose proportionality assessment following single doses to healthy subjects
J Clin Pharmacol.
(2001)
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women
Biopharm Drug Dispos.
(2000)
Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG Protocol 251
J Clin Pharmacol.
(2001)
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267
J Infect Dis.
(2002)
Thalidomide treatment for chronic graft-versus-host disease
Br J Haematol.
(1991)
High-performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease
Ann Clin Biochem.
(1995)
Low bioavailability of rectally administered thalidomide
Am J Health Syst Pharm.
(2000)
Thalidomide is distributed into human semen after oral dosing
Drug Metab Dispos.
(2001)
Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients
J Biochem Mol Toxicol.
(2000)
The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species
Br J Pharmacol.
(1965)
The chemistry and metabolism of thalidomide
Pharmacologic properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug
Br J Pharmacol.
(1960)
Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
J Exp Med.
(1991)
Cited by (191)
Toxicologic pathology of the reproductive system
2022, Reproductive and Developmental ToxicologyDrug repurposing for breast cancer therapy: Old weapon for new battle
2021, Seminars in Cancer BiologyApplication of a human mesoderm tissue elongation system in vitro derived from human induced pluripotent stem cells to risk assessment for teratogenic chemicals
2020, ChemosphereCitation Excerpt :Not only genetic disorders in babies but also infections in pregnant women are risks for stillbirths and congenital diseases. Developmental processes are also disturbed by exposure to various transplacental chemicals from the diet and medication of pregnant women, such as thalidomide (Matthews and McCoy, 2003). Heavy metals are also known as teratogenic risk factors during human ontogeny (Clemens and Ma, 2016; Jin et al., 2016; Vejrup et al., 2018).
Oral Lichen Planus and Lichenoid Lesions: Etiopathogenesis, Diagnosis and Treatment
2023, Oral Lichen Planus and Lichenoid Lesions: Etiopathogenesis, Diagnosis and Treatment
Copyright © 2003 Published by Elsevier Inc.